buy

Regeneron Pharmaceuticals Inc. buy Guggenheim

Regeneron Pharmaceuticals Inc.

Start price

€973.80

/ 50%

Target price

19.07.25

Performance (%)

End price

€469.20

Summary

This prediction ended on with a price of €469.20. The BUY prediction by Guggenheim for Regeneron Pharmaceuticals Inc. performed very badly with a performance of . Guggenheim has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. A total of was paid as dividends for this prediction. Guggenheim has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Feedback

Performance without dividends (%)

Name	1w	1m	1y
Regeneron Pharmaceuticals Inc.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by Guggenheim for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren

Prediction Buy

Perf. (%)

Target price 1082.532

Change

Ends at

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Guggenheim from $1,040.00 to $1,180.00. They now have a "buy" rating on the stock.

Ratings data for REGN provided by MarketBeat

Guggenheim